Table 1.
Patient characteristics.
| N (%) | |
|---|---|
| Age, years | |
| Median | 58 |
| Range | 37–85 |
| Gender, male/female | 68/6 |
| Smoking, yes | 57 (77.0%) |
| Betel nut chewing, yes | 51 (68.9%) |
| EGFR, positive | 74 (100%) |
| P-16 | |
| Positive | 14 (18.9%) |
| negative | 51 (68.9%) |
| unknown | 9 (12.2%) |
| Primary cancer sites | |
| Oral cavity | 35 (47.3%) |
| Oropharynx | 22 (29.7%) |
| Hypopharynx or larynx | 17 (23.0%) |
| Original AJCC stage | |
| I | 1 (1.4%) |
| II | 2 (2.8%) |
| III | 14 (18.8%) |
| IVa | 37 (50.0%) |
| IVb | 20 (27.0%) |
| Recurrent AJCC stage | |
| rcIVa | 8 (10.8%) |
| rcIVb | 66 (89.2%) |
| Previous surgery | 66 (89.2%) |
| Previous chemotherapy | 74 (100%) |
| Previous RT dose, Gy | |
| Median | 70 |
| Range | 60–120 |
| Re-irradiation interval, months | |
| Median | 22 |
| Range | 1–145 |
| SBRT, sites | |
| T | 38 (51.4%) |
| N | 19 (25.6%) |
| T + N | 17 (23.0%) |
| SBRT, total dose (Gy) | |
| Median | 40 |
| Range | 40–50 |
| SBRT, dose per fraction (Gy) | |
| Median | 8 |
| Range | 8–10 |
| GTV, median (range), ml | 64.5 (9.0–358.7) |
| ≦50 | 25 (33.8%) |
| 50-100 | 22 (29.7%) |
| ＞100 | 27 (36.5%) |
| PET-CT, delayed SUVmax | |
| Median | 10.6 |
| Range | 3.3–22.7 |
Abbreviations: RT: radiotherapy; SBRT: stereotactic body radiotherapy; T: gross tumor area; N: gross nodal area; GTV: gross tumor volume; PET-CT: Positron emission tomography–computed tomography scans; AJCC: American Joint Committee on Cancer Staging System, 8th edition.